Helius Medical Technologies, Inc. (HSDT): Market Cap to Revenue
The price-to-sales multiple helps determine the boundaries of business value, with the current figure standing at 7.30. Transparent commercialization of the neuroplatform and management's expertise in handling insurance reimbursements minimize risks. An eco-friendly approach to creating energy-efficient stimulation systems reduces environmental impact. Helius Medical (HSDT) is currently scaling the deployment of PoNS devices by expanding its clinic network and training US specialists.
Analytical breakdowns for Helius Medical (HSDT)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book value of equity indicators:
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Helius Medical|HSDT - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio heliusmedical.com|HSDT - Company Aggregate Debts|Debts to Book Capitalization Helius Medical Technologies Inc.|HSDT - Company Long-Term Debt|Company Short-Term Debt Helius Medical Technologies|Intermediate Coverage Ratio heliusmedical.com
- earnings and multiples data:
HSDT - Company Net Income|Company Profit Forecast Helius Medical|HSDT - P/E Multiple|Price to Future Earnings Ratio heliusmedical.com|HSDT - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Helius Medical Technologies Inc.|HSDT - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Helius Medical Technologies|HSDT - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months heliusmedical.com|HSDT - Net earnings per share growth this year|Earnings growth forecast for next year Helius Medical
- issuer revenue and sales details:
General company analysis:HSDT Helius Medical Technologies, Inc.
To assess the investment attractiveness of Helius Medical (HSDT), it is essential to compare the business's market value with its actual revenue. By analyzing the company's historical P/S ratio on GURU.Markets, an investor determines how many dollars of market capitalization are attributed to one dollar of sales. This multiple is critical for Helius Medical (HSDT), as outsourcing production and support reduces capital expenditures. A rise in share prices without a proportional increase in revenue signals that the asset is overvalued.
Competitors of Helius Medical
BIIB (biogen.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|RGC - Market Cap to Revenue|Axsome Therapeutics Inc - P/S Multiple|Price to Sales ACADIA Corp|XENE: P/S Multiple|Market Cap to Revenue Ratio VKTX|SUPN (Supernus) - P/S Multiple|Catalyst Pharma (CPRX) - Price-to-Revenue Coefficient|P/S Multiple DNLI|Market Cap to Revenue Harmony Corp HRMY|P/S Multiple BHVN (Biohaven Ltd.)|P/S Multiple amylyx.com AMLX|TRVI - Price-to-Revenue Ratio|PRAX: Price-to-Revenue Ratio|AVXL: P/S Multiple|CeriBell EEG - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Prothena Biosciences|Alector Therapeutics (ALEC) - Price-to-Revenue Coefficient|P/S Multiple ANNX|omeros.com - Market Cap to Revenue Ratio|Neurogene Corp - Market Cap to Revenue|Market Cap to Sales Volume ACIU (AC Immune Inc)|VYGR - Price-to-Revenue Ratio|NMRA (neumoratx.com) - Market Cap to Revenue Ratio|SCLX: P/S Multiple|Price to Sales Tevogen Bio Holdings Inc. (TVGN)|Market Cap to Revenue ACOG|P/S Multiple Cognition Therapeutics Inc.|Price-to-Revenue Ratio Inhibikase Therapeutics (IKT)|SAVA (cassavasciences.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Assertio ASRT|Coya Therapeutics Inc (COYA) - Price to Sales|VistaGen Therapeutics Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio OVID (Ovid Therapeutics Inc.)|ABOS: P/S Multiple|Price to Sales cervomed.com (CRVO)|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|Price-to-Revenue Ratio CLNN|P/S Multiple PEPG|Price-to-Revenue Coefficient Jupiter Neurosciences, Inc.|Relmada Therapeutics - Market Cap to Revenue|P/S Multiple annovisbio.com ANVS|GRCE - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Firefly Neuroscience, Inc. AIFF|KLTO (anewmeds.com) - Market Cap to Revenue|NeuroSense Therapeutics Ltd. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Reviva Pharmaceuticals|Market Cap to Revenue MetaVia, Inc. (MTVA)|P/S Multiple NRXS|PASG - Price to Sales|P/S Multiple NEUP (Neuphoria Therapeutics)|NERV: Market Cap to Revenue Ratio|Athira Pharma, Inc. - P/S Multiple|Price-to-Revenue Coefficient addextherapeutics.com ADXN|ALZN: P/S Multiple|Market Cap to Revenue Cyclerion Therapeutics, Inc.|PTIX (Protagenic Therapeutics Inc.) - P/S Multiple|P/S Multiple Pasithea|Price-to-Revenue Ratio Cortigent, Inc. (CRGT)|Price-to-Revenue Ratio ATXI (avenuetx.com)|P/S Multiple BCLI (BrainStorm Cell Therapeutics)|Market Capitalization-to-Revenue Ratio CARA|CHRO - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Eliem Therapeutics ELYM|ITCI: P/S Multiple|Market Cap to Revenue Ratio LBPH|Market Cap to Revenue MRNS|NKGN (NKGen Biotech Inc) - Market Cap to Sales Volume|Price-to-Revenue Ratio NeuroBo (NRBO)|Sage Therapeutics Inc - Market Cap to Revenue Ratio|P/S Multiple SNPX (Synaptogenix, Inc.)|trevena.com (TRVN) - Price to Sales|VIGL: Market Cap to Revenue|WENA - P/S Multiple|Cerevel (CERE) - Price-to-Revenue Ratio
